ANTX vs APVO

AN2 Therapeutics, Inc. vs Aptevo Therapeutics Inc. — Valuation Comparison 2026

ANTX

Pharmaceutical Preparations
AN2 Therapeutics, Inc.
Quality
4.3
out of 10
Value Trap
18
SAFE
Price
$4.33
Last close
Models
7/13
Active
VS

APVO

Pharmaceutical Preparations
Aptevo Therapeutics Inc.
Quality
4.2
out of 10
Value Trap
24
SAFE
Price
$4.91
Last close
Models
6/13
Active

Model-by-Model Comparison

ModelType ANTX Fair ValueANTX Upside APVO Fair ValueAPVO Upside
Bayesian DCF Intrinsic $2.08 -52.0% $6.09 +24.1%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $0.39 -91.1% $0.36 -92.6%
Dynamic NAV Asset-Based $•••.•• ••.•% $•••.•• ••.•%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for ANTX vs APVO — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

ANTX vs APVO — Which Stock Is More Undervalued?

ANTX scores higher with a 4.3/10 quality rating vs APVO's 4.2/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing AN2 Therapeutics, Inc. (ANTX) and Aptevo Therapeutics Inc. (APVO) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

ANTX currently trades at $4.33 with a QOC of 4.3/10, while APVO trades at $4.91 with a QOC of 4.2/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).